Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kura Oncology (KURA) EBIT Margin (2024 - 2025)

Historic EBIT Margin for Kura Oncology (KURA) over the last 2 years, with Q3 2025 value amounting to 385.53%.

  • Kura Oncology's EBIT Margin fell 149204800.0% to 385.53% in Q3 2025 from the same period last year, while for Sep 2025 it was 482.11%, marking a year-over-year change of. This contributed to the annual value of 358.55% for FY2024, which is 110624800.0% down from last year.
  • Per Kura Oncology's latest filing, its EBIT Margin stood at 385.53% for Q3 2025, which was down 149204800.0% from 475.31% recorded in Q2 2025.
  • Kura Oncology's 5-year EBIT Margin high stood at 14534.95% for Q3 2024, and its period low was 475.31% during Q2 2025.